$-0.14 EPS Expected for Stellar Biotechnologies Inc (SBOT)

November 15, 2017 - By Darrin Black

 $ 0.14 EPS Expected for Stellar Biotechnologies Inc (SBOT)

Analysts await Stellar Biotechnologies Inc (NASDAQ:SBOT) to report earnings on December, 13. They expect $-0.14 earnings per share, down 7.69 % or $0.01 from last year’s $-0.13 per share. After $-0.12 actual earnings per share reported by Stellar Biotechnologies Inc for the previous quarter, Wall Street now forecasts 16.67 % negative EPS growth. The stock decreased 2.34% or $0.03 on November 14, reaching $1.08. About 15,284 shares traded. Stellar Biotechnologies Inc (NASDAQ:SBOT) has declined 60.19% since November 15, 2016 and is downtrending. It has underperformed by 76.89% the S&P500.

Stellar Biotechnologies, Inc. is a biotechnology company. The company has market cap of $11.36 million. The Firm is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin . It currently has negative earnings. KLH is an immune-stimulating protein.

More recent Stellar Biotechnologies Inc (NASDAQ:SBOT) news were published by: Streetinsider.com which released: “Stellar Biotechnologies (SBOT) to Sell ‘Immunogen & Vaccine Technology’ to …” on March 13, 2017. Also Marketwired.com published the news titled: “Stellar Biotechnologies Advances Strategic Plan to Secure Key Production Region” on January 11, 2017. Marketwired.com‘s news article titled: “The Life Sciences Report Examines Stellar Biotechnologies (SBOT:NASDAQ) Inking …” with publication date: March 06, 2017 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.